Work

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Year: 2018

Type: article

Study design: Case Report

Abstract: HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofy221

Authors: Jomy M George, Safia S Kuriakose, Nicola Dee, Pam Stoll, Tahaniyat Lalani, Robin Dewar, Muhammad A Khan, Muhammad T Rehman, Zehava Grossman, Frank Maldarelli, Alice K Pau

Institutions: National Institutes of Health, National Institutes of Health Clinical Center, Frederick National Laboratory for Cancer Research, National Cancer Institute, Uniformed Services University of the Health Sciences, Tel Aviv University, National Institute of Allergy and Infectious Diseases

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053

Funders: National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases

Awards: G1286242323, G386607036, G5888954722, G8442469067

OpenAlex ID: W2890474156

FWCI: 1.575

Cites: 14

Cited by: 28

Related to: 10